文献速递角膜与眼表疾病

SARS-CoV-2疫苗接种后疫苗相关的角膜移植排斥反应:CDC-VAERS数据库分析

Vaccine-associated corneal graft rejection following SARS-CoV-2 vaccination: a CDC-VAERS database analysis.
PubMed 文献 · Br J Ophthalmol · 2023-12-18

该研究分析了CDC-VAERS数据库中SARS-CoV-2疫苗接种后角膜移植排斥反应的病例,共纳入46例患者55只眼,主要接种BNT162b2(73.91%)和mRNA-1273(26.09%)。结果显示排斥反应发生时间在第二剂疫苗后较第一剂和加强剂后显著更短(p=0.0165),内皮角膜移植术后较穿透性角膜移植术后显著更短(p=0.041)。研究提示角膜移植排斥与SARS-CoV-2疫苗接种之间可能存在时间关联。

要点

  • 55只眼(46例患者)在SARS-CoV-2疫苗接种后发生角膜移植排斥,BNT162b2占73.91%,mRNA-1273占26.09%。
  • 第二剂疫苗后排斥发生时间较第一剂和加强剂后显著更短(p=0.0165)。
  • 内皮角膜移植术后排斥发生时间较穿透性角膜移植术后显著更短(p=0.041)。

核心结论

  • 本研究概述了角膜移植排斥与SARS-CoV-2疫苗接种之间可能存在的时间关联。
  • 在有内皮角膜移植术病史的患者中以及第二剂疫苗接种后观察到排斥反应发生更早。

研究设计与样本

  • 对CDC-VAERS数据库中SARS-CoV-2疫苗接种后角膜移植排斥病例进行描述性分析,评估人口学、临床病史和表现。
  • 采用单因素方差分析检验疫苗与疫苗相关排斥发生时间的相关性,并进行事后分析比较不同疫苗剂量和疫苗类型后的排斥发生间隔。
  • 进行30天累积发病率分析以评估不同剂量、疫苗和角膜移植类型后短期排斥风险。

主要发现

  • 共纳入46例患者55只眼,平均年龄62.76±15.83岁,女性28例(60.87%)。
  • 接种疫苗为BNT162b2(73.91%)和mRNA-1273(26.09%)。
  • 角膜移植类型包括穿透性角膜移植术(61.82%)、Descemet膜内皮角膜移植术(12.73%)、Descemet剥离内皮角膜移植术(18.18%)、前板层角膜移植术(3.64%)和角膜缘同种异体移植术(1.82%)。
  • 穿透性角膜移植术后排斥发生平均时间为8.42±9.23年,内皮角膜移植术后为4.18±4.40年。
  • 45.65%的排斥病例在第二剂疫苗后报告。

关键数值与推荐

  • 共55只眼(46例患者)诊断为疫苗接种后角膜移植排斥。
  • 第二剂疫苗后排斥发生时间较第一剂和加强剂后显著更短(p=0.0165)。
  • 内皮角膜移植术后排斥发生时间较穿透性角膜移植术后显著更短(p=0.041)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the cases of corneal graft rejection following SARS-CoV-2 vaccination reported to Centers for Disease Control and Prevention Vaccine Adverse Event Reporting System. METHODS: A descriptive analysis of the demographics, clinical history and presentation was performed. We evaluated the correlation between the vaccines and duration of vaccine-associated graft rejection (VAR) onset following vaccination using a one-way analysis of variance test. A post hoc analysis was performed between VAR onset-interval following vaccination dose and vaccine type. Finally, a 30-day cumulative incidence analysis was performed to assess the risk of VAR in short term following different doses, vaccines and type of corneal transplantation. RESULTS: A total of 55 eyes of 46 patients were diagnosed with VAR following vaccination with BNT162b2 (73.91%) and mRNA-1273 (26.09%). The mean age of the patients was 62.76±15.83 years, and 28 (60.87%) were female. The patients diagnosed with VAR had undergone penetrating keratoplasty (61.82%), Descemet membrane endothelial keratoplasty (12.73%), descemet stripping endothelial keratoplasty (18.18%), anterior lamellar keratoplasty (3.64%) and corneal limbal allograft transplantation (1.82%). The mean time for VAR since penetrating and endothelial keratoplasty was 8.42±9.23 years and 4.18±4.40 years, respectively. 45.65% of the cases of VAR were reported after the second dose of vaccine. The duration of VAR onset was significantly shorter after the second dose compared with the first and booster doses (p=0.0165) and in patients who underwent endothelial keratoplasty compared with penetrating keratoplasty (p=0.041). CONCLUSIONS: This study outlines a possible temporal relationship between corneal graft rejection and SARS-CoV-2 vaccination. An earlier onset of VAR was observed in patients who had a history of endothelial keratoplasty and following the second dose of vaccination.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Singh RB, Li J, Parmar UPS, et al. Vaccine-associated corneal graft rejection following SARS-CoV-2 vaccination: a CDC-VAERS database analysis. Br J Ophthalmol. 2023. PMID: 36575625. doi:10.1136/bjo-2022-322512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。